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Background: This study was to compare radiotherapy treatment planning and treatment outcomes following
three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) in stage I-II natural
killer (NK)/T-cell lymphoma.
Methods: The cases of 94 patients with stage I-II NK/T-cell lymphoma, nasal type in the upper aerodigestive tract
who treated between May 2005 and Dec 2008 were reviewed. These patients received radiotherapy with or
without induction chemotherapy. Definitive radiotherapy was conducted using 3DCRT in 47 patients and IMRT in
the other 47 patients with a regional field and a total dose of 50 Gy. Dosimetric parameters of radiation treatment
plans, local control probability (LCP), overall survival (OS), and toxicities were analyzed and compared between
3DCRT and IMRT.
Results: From the dosimetric analysis, IMRT demonstrated significantly better dose coverage and homogeneity
than 3DCRT. However, after a median follow-up of 46 months, IMRT was not associated with improvements in
4y-OS (80.9% for 3DCRT vs. 82.7% for IMRT, p=0.87) or 4y-LCP (86.3% for 3DCRT vs. 88.9% for IMR p=0.85). Of the
18 patients who received cervical lymph node irradiation, those in the IMRT group received a lower mean parotid
dose. Furthermore, at-risk organs were strictly kept within the safe dose range in both groups, and no severe late
toxicity was observed.
Conclusions: IMRT provided better dose coverage than 3DCRT, although it failed to provide LCP and OS benefits.
Definitive radiotherapy with a regional field and a total dose of 50 Gy is efficient and safe for NK/T-cell lymphoma
using either IMRT or 3DCRT. However, IMRT may have the potential to reduce parotid gland hypofunction following
cervical irradiation.
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http://www.ro-journal.com/content/8/1/152Extranodal nature killer (NK)/T-cell lymphoma, nasal type
is an aggressive type of lymphoma [1], which has been for-
mally identified and classified as a distinct clinicopatho-
logic entity according to the WHO classification in 2001.
Clinically, this type of lymphoma is characterized by the
presence of destructive disease in mid-facial structures.
Although rarely diagnosed in Western countries, this
subtype is prevalent in certain areas of Central America,
South America, and East Asia [2]. The nasal cavity is the
most commonly involved site of primary disease. Tumors
with a same phenotype and genotype that are located in a
variety of extranodal sites other than the nasal cavity are
referred to as nasal-type tumors [3].
Although approximately 80% of cases diagnosed with
localized disease are of stage I-II [4], treatment out-
comes remain unsatisfying. In comparison to other
subtypes of NHL, NK/T-cell lymphoma is relatively
resistant to anthracycline-based chemotherapy [2,4-6],
although it demonstrates a rapid and dramatic response
to radiotherapy [4,5,7-10]. As radiotherapy is regarded
as the primary therapy for stage I-II NK/T-cell lymph-
oma, the construction of feasible and optimal patterns of
radiotherapy is critical. Nevertheless, the low incidence
of NK/T-cell lymphoma and its confusing nomenclature
has made it difficult to perform large-sample, pros-
pective, randomized clinical trials. As a result, optimal
radiotherapeutic models, including radiation field, dose
and treatment plans, have not been properly established.
Though highly conformal radiation techniques have
been widely studied in head-and-neck cancer, previous
investigation of NK/T lymphoma treated with IMRT or
3DCRT is rare. The only study was reported by Wang
H, et al. [11]. They got a favorable prognosis (the 2-year
LRC, OS rate was 93% and 78%, respectively) and mild
toxicity in 42 nasal NK/T-cell lymphoma cases with
IMRT techniques. In comparison to IMRT, 3DCRT has
poor conformal planning treatment volume (PTV) cover-
age, organ at risk (OAR) avoidance, and higher toxicity
rates for a variety of cancers [12-15]. In contrast, with the
use of complex computerized treatment planning, IMRT
is time consuming and carries large technical require-
ments. Tomita et al. [16] concluded that IMRT provides a
dosimetric advantage over 3DCRT in terms of PTV cover-
age, according to an analysis of radiotherapy treatment
plans in NK/T-cell lymphoma cases. However, the clinical
date comparing IMRT and 3DCRT was still lacking.
In this study, we compared the two widely used ra-
diotherapeutic techniques of 3DCRT and IMRT for the
treatment of NK/T-cell lymphoma using statistically valid
methodologies. 3DCRT and IMRT were compared in
terms of differences in PTV dose coverage and OAR spar-
ing. Moreover, the clinical results of these two techniques
were analyzed, particularly regarding LCP, OS, prognostic
factors, and radiotherapy-related adverse events.Methods
This was a retrospective, single-center study. We made our
sample selection from 119 continuous treated patients who
had pathological diagnoses of extranodal NK-T cell lymph-
oma, nasal type at the institute between May 2005 and
December 2008. Eligible patients needed to have previously
untreated Ann Arbor stage I-II disease within the upper
aerodigestive tract. This study sought to compare the treat-
ment outcomes and toxicity levels between the 3DCRT and
IMRT radiotherapy techniques. Patients with the following
conditions were excluded: 1) previous head and neck irradi-
ation exposure; 2) death from disease progress or adverse
toxicity during or right after induction chemotherapy; and
3) declination to receive definitive radiotherapy for various
reasons (mental disease or personal decision).
Patient characteristics
Ninety-four patients were identified as fulfilling our inclu-
sion criteria (Table 1). The median patient age was 44 years
(range, 14–73). The male/female ratio was 2.4:1. Of these,
76 patients were in stage I and 18 patients were in stage II
with positive cervical lymph nodes according to Ann Arbor
staging. Most of the patients (85.1%) had primary disease in
the nasal cavity, whereas the other patients had disease ori-
ginating in the nasopharynx, oropharynx or tonsil. Forty-
seven cases were treated with 3DCRT, and the others were
treated with IMRT. Following the development of radiation
techniques at our institution, the percentage of IMRT usage
was increased significantly after 2007, from 19.3% between
2005 and 2007 to 97.3% during 2008.
Treatment
Of the 94 patients included, 11 were treated with definitive
radiotherapy alone. The remaining 83 patients were treated
with a combined treatment consisting of one to four cycles
of induction chemotherapy and definitive radiotherapy, as
shown in Table 1. The choice to administer induction che-
motherapy was decided by the physicians. Those patients
demonstrating high risk factors, such as stage II disease, B
symptoms, or large extensions of primary lesions, generally
underwent induction chemotherapy.
Two chemotherapy regimens were applied: CEOP (cyclo-
phosphamide, epirubicin, vincristine, prednisone) for 29
patients and DICE (etoposide. cyclophosphamide cisplatin,
dexamethasone) for 54 patients. Both treatments were re-
peated every 3 weeks. Considering the evidence demon-
strating the relative resistance of NK/T-cell lymphomas to
anthracycline-based chemotherapy regimens [4,5], CEOP
regimens were gradually replaced by DICE regimens at our
institution fromMar 2006.
Radiotherapy
All patients were immobilized in a supine position with
a thermoplastic head mask and simulated by CT using a
Table 1 Patient characteristics















































anasal cavity lesions with limited invasion: the tumor invaded nasal cavity and
one neighboring anatomic structure (paranasal sinus or nasopharynx).
bnasal cavity lesions with extensive invasion: the tumor invaded nasal cavity
and two or more neighboring anatomic structures(paranasal sinuses,
nasopharynx, oropharynx or laryngopharynx).
cNon-nasal cavity originated: the tumor originated from nasopharynx,
oropharynx, laryngopharynx or tonsil.
Abbreviations: LDH lactate dehydrogenase, ECOG Eastern Cooperative
Oncology Group, mIPI Stage-modified International Prognostic Index,
CEOP cyclophosphamide, epirubicin, vincristine prednisone, DICE etoposide.
cyclophosphamide cisplatin, dexamethasone.
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ferior of the clavicular heads.
The gross tumor volume (GTV) was determined ac-
cording to CT or MRI analysis and endoscopic findings.
The clinical target volume (CTV) consisted of the GTV
and adjacent structures with potential involvement. If
the neck lymph nodes were involved, the ipsilateral neck
was irradiated. No prophylactic cervical irradiation was
delivered. The CTV was expanded by 5 mm to obtain
the PTV, and one example of PTV delineation is shown
in Figure 1.
The requirements for the treatment plans were as fol-
lows: 1) 100% of the PTV volume received at least 95% of
the prescription dose and more than 95% of the PTV vol-
ume received a 100% prescription dose; and 2) less than
5% of the PTV volume received more than 110% of the
prescribed dose. OARs included the brainstem, spinal
cord, lenses, eyes, and parotid glands. According to pub-
lished QUANTEC articles [17], the dose constrictions of
the OARs were as follows: brainstem, maximum dose <50
Gy; spinal cord, maximum dose ≤45 Gy; lens, maximum
dose 10 <Gy; parotid glands, mean dose <26 Gy.
A three-field 3DCRT technique using one anterior
portal and two lateral fields with 6 MV was applied. In
addition, an appropriate 9-MeV or 12-MeV electron
beam was used to compensate the insufficiency dose of
the anterior ethmoid. For IMRT planning, 5–7 fields
were given. The prescription was for 50 Gy in 25 frac-
tions at 2 Gy per day for 5 days per week.
Comparison criteria for the radiation treatment plans
The data from the dose volume histograms (DVHs)
obtained from each patient were analyzed. Representative
dose distribution and DVHs for 3DCRT and IMRT are
shown in Figures 1 and 2. The dose coverage was analyzed
according to the minimum dose (Dmin), maximum dose
(Dmax), mean dose (Dmean), V95% (i.e., the percent of the
volume that receives x% of the prescription), V90%, V105%,
V110%, conformity index (CI), and homogeneity index
(HI). The CI was defined as follows [18]:
CI ¼ VRI
PTV
where VRI represents the volume covered by the prescrip-
tion dose (50 Gy). A CI value of 1.0 indicates that the vol-
ume of the prescription isodose surface is equal to that of
the PTV. The HI was defined as follows [19]:
HI ¼ D2−D98
D50
where Dx% represents the dose delivered to x% of the
PTV. Lower HI values indicate a more homogeneous
target dose. OARs (e.g., the parotid glands, lens, eyeballs,
Figure 1 Example of the dose distribution using 3DCRT and IMRT. This patient had a tumor limited to the bilateral nasal cavity and
nasopharynx and obtained CR following induction chemotherapy. The PTV (volume in red) included the nasal cavity, ethmoid sinus, maxillary
sinus, nasopharynx and laryngopharynx. The top row and the bottom row show the dose distributions for IMRT and 3DCRT, respectively.
Shen et al. Radiation Oncology 2013, 8:152 Page 4 of 8
http://www.ro-journal.com/content/8/1/152brainstem, and spinal cord) were compared according to
the values of Dmax and Dmean.
Follow-up
The median duration of follow-up was 46 months, and
the median duration of follow-up for the surviving pa-
tients was 50.4 months. For the 3DCRT group and the
IMRT group, the median duration of follow-up for theFigure 2 DVH for the 3DCRT and IMRT plans for the same
patient shown in Figure 1. The solid lines and the dash lines
represent the DVH of 3DCRT and IMRT, respectively.surviving patients was 59.6 (46.5-73.3) months and 40.9
(35.0-56.1) months, respectively. All patients were re-
gularly followed until death or the last follow-up at 3- to
6-month intervals. Tumor responses were assessed one
month after the completion of RT using image methods,
including endoscopic examinations, CT or MRI scans of
the head and neck, or positron emission tomography.
According to the CTCAE 3.0 criteria, the clinicians
estimated radiation-related adverse events such as oral
mucositis, xerostomia, or decreased visual acuity.
Statistical analysis
Tumor response to radiotherapy was evaluated according
to the Revised Response Criteria of Malignant Lymphoma
[20]. OS was defined as the date of diagnosis to either the
date of death from any cause or the last follow-up visit.
LCP was calculated according to the date of diagnosis
until the date of in-field or marginal recurrence.
The comparison of parameters between IMRT and
3DCRT was calibrated using an independent samples
t-test. The Kaplan-Meier method was used to calculate
the LCP and OS curves. The log-rank test was per-
formed for treatment comparisons in the univariate
analysis. Moreover, all variables with a p value of <0.05
in the univariate analyses, in addition to radiation
technique (IMRT or 3DCRT), were included in the
multivariate model using the Cox proportional hazards
regression model. Two-sided p values <0.05 were con-
sidered significant.
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Treatment plan: dose coverage and OAR sparing
Parameters related to dose coverage planning for
3DCRT and IMRT are presented in Table 2. The results
indicated that IMRT showed better PTV coverage. The
V95% for IMRT was 96.17±13.36%, whereas that for
3DCRT was 85.40±27.04% (p=0.02). However, this ad-
vantage for IMRT was not observed for the comparison
of V90%. The hot dose volume of 105% with IMRT was
larger than that for 3DCRT, whereas the V110% value was
smaller for IMRT. As dose coverage (V90%, V95%, V105%,
V110%), there was no significant difference observed,
which is independent of undergoing cervical lymph node
irradiation or not. The IMRT plan was also less homoge-
neous than that for 3DCRT with marginal significance
(HI for 3DCRT: 0.20±0.11 vs. HI for IMRT: 0.10±0.03
p=0.05), whereas there was no significant difference
between the IMRT and 3DCRT plans in terms of dose
conformity (CI: 1.28±0.18 for 3DCRT vs. 1.08±0.16 for
IMRT, p=0.07).
Regarding the comparison of parotid Dmean, there was
no significant difference between 3DCRT and IMRT
(Dmean: 22.12±9.30 Gy for 3DCRT vs. Dmean: 20.91±6.56
Gy for IMRT, p=0.31). The result of 18 patients re-
ceiving cervical lymph node irradiation concludes to a
higher parotid Dmean comparing to the counterpart 76
patients not receiving the corresponding irradiation
(Dmean: 31.49±7.09 Gy vs. 20.93±6.66 Gy, p=0.00).
Among the patients receiving cervical irradiation, those
in the IMRT group (10 patients) demonstrated lower
parotid Dmean, values in comparison to those in the
3DCRT group (8 patients) (IMRT: 27.23±7.0 Gy vs.
3DCRT: 32.93±9.69 Gy, P<0.05). The average maximal
dose to the brainstem, spinal cord and lens (3DCRT vs
IMRT) was 45.4 vs 41.4, 39.3 vs 32.5, and 7.5 vs 5.7 Gy,
respectively. The average mean dose to eyeball was 13.2
vs 8.9 Gy for 3DCRT and IMRT, respectively. Similar to
the parotid glands, the dosimetric details for the spinal cord,
brainstem, lens, and eyeball demonstrated no significantTable 2 PTV dose coverage
3DCRT IMRT p value
Dmax(Gy) 59.25±6.71 57.18±2.17 0.05
*
Dmean(Gy) 51.73±1.01 52.06±1.14 0.14
V95%(%) 85.40±27.04 96.17±13.36 0.02
*
V90%(%) 98.70±3.32 98.99±1.81 0.60
V105%(%) 28.53±19.09 44.44±21.11 <0.01
*
V110%(%) 7.14±7.92 4.19±5.10 0.04
HI 0.20±0.11 0.10±0.03 0.05*
CI 1.28±0.18 1.08±0.16 0.07
*variable with significant difference.
Dmax maximum dose, Dmean mean dose, Vx% percent of volume receives x% of
the prescription, CI conformity index, HI homogeneity index.differences between the IMRT and 3DCRT plans and all
of these organs were strictly maintained within the dose
limitations.
Treatment response
Dramatic responses were observed in both the 3DCRT
and IMRT groups. Complete remission (CR) was achieved
in 46 of 47 patients (97.9%) in the 3DCRT group and in 45
of 47 patients (95.7%) in the IMRT group after the com-
pletion of all treatments.
Moreover, all 11 patients (10 in the 3DCRT group and
1 in the IMRT group) who were treated with radiation
alone achieved CR. The CR rate was 31.3% following
induction chemotherapy for 83 patients treated with
chemoradiantion, and it rose to 97.3% in 3DCRT group
and 97.8% in IMRT group respectively after completion
of radiotherapy.
In the 3DCRT group, 91.5% of the patients completed
the radiotherapy treatment to the total dose of 50 Gy.
Three patients stopped radiotherapy at a total dose of
44–48 Gy due to oral mucositis, and one patient stopped
treatment due to a pulmonary infection at a total dose
of 28 Gy. In the IMRT group, 93.6% of the patients
completed the radiotherapy treatment. Three patients
discontinued treatment due to systemic progression at
total doses of 12 Gy, 38 Gy, and 46 Gy.
Treatment outcome and prognostic factors
The 4-year OS and 4-year LCP rates were 81.1%, and
87.2% for all patients, respectively. Treatment failures
occurred in 31 patients, including 23 cases of systemic
recurrence, 3 cases of residual lesions and 9 cases of
local relapse (8 in-field or marginal recurrence and 1
outside-field recurrence in the gingiva). No cervical fail-
ure was observed.
All the variables (Sex, Male, Age, ECOG score, Stage, “B”
symptoms, LDH level, Primary site, Stage-modified IPI,
Induction chemotherapy, Response to induction chemo-
therapy, Radiotherapy) were under the univariate analysis
(Additional file 1: Table e1). IMRT was not associated with
improvement in terms of 4y-OS (80.9% for 3DCRT vs.
82.7% for IMRT, p=0.87) and 4y-LCP (86.3% for 3DCRTvs.
88.9% for IMRT, p=0.85) (Figure 3).
The significant factors identified in the univariate ana-
lysis (listed in Table 3), in addition to the radiotherapy
technique (IMRT or 3DCRT), were also accounted for
in the multivariate analysis. Independent poor prognos-
tic factors for LCP included an ECOG score of 2 (hazard
ratio: 2.23; 95% CI: 0.76-6.54; P=0.02), while an ECOG
score of 2 (hazard ratio: 2.59; 95% CI: 1.08-6.22; P=0.03)
and elevated LDH level (hazard ratio: 3.05; 95% CI: 1.03-
9.06; P=0.04) were shown to be factors associated with
poor OS. IMRT was also not found to be associated with
improved LCP or OS.
Figure 3 LCP (a) and OS (b) in patients treated with 3DCRT or IMRT.
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Oral mucositis was the most common type of toxicity,
although only three patients ceased treatment due to
grade IV oral mucositis (all in 3DCRT group). Following
a long time follow-up, late toxicity was observed. In both
3DCRT group and IMRT group, 43/47 patients (91.5%)
and 42/47 patients (89.4%) had toxicity data at 1 year
and 2 years follow-up, respectively. There was no signifi-
cantly different rate of xerostomia between the IMRT
group and the 3DCRT group(12.8% Grade I; 6.4% Grade
II for 3DCRT vs. 21.3% Grade I; 4.2% Grade II for IMRT,
no higher grade xerostomia was observed). However, it
was observed a lower xerostomia rate in patients not
receiving cervical irradiation. In clinical follow-up, grade
I and II xerostomia rate reached to 38.9% in cervical
irradiation group while it was only 18.4% in no cervical
irradiation group. Among those 18 cases who underwent
cervical irradiation, IMRT group (10 patients) showed a
lower rate of xerostomia (30% grade I cases and no ser-
ious cases), while 3DCRT group (8 patients) demon-
strated a 38% grade I and 12% grade II xerostomia rate.





ECOG score =2 2.59(1.08–6.22)
LDH elevated¶ 3.05(1.03–9.06)
Stage = II± –
Nasal cavity lesions with extensive invasion& 1.30(0.83–2.06)
Stage-modified IPI=2-3 0.95(0.40–2.24)
¶LDH elevation was accounted for in the multivariate analysis for LCP, but not for O
±Stage = 2 was accounted for in the multivariate analysis for OS, but not for LCP.
&Nasal cavity lesions with extensive invasion: the tumor invaded nasal cavity and tw
oropharynx or laryngopharynx).whereas 1 patient in the 3DCRT group experienced hy-
posmia. No cataracts or nervous system disorders were
observed during follow-up.
Discussion
Both the 3DCRT and IMRT are widely used and each
has some specific advantages. The IMRT shows superior
dosimetric benefits while the 3DCRT is easy to imple-
ment even for those Linac without IMRT feasibility. The
current study found that for cases of NK/T-cell lymph-
oma, IMRT demonstrated improved dose coverage but
was equivalent to 3DCRT in terms of LCP, OS and
toxicity. Furthermore, definitive radiotherapy with a re-
gional field to a total dose of 50 Gy was shown to be ef-
ficient and safe for NK/T-cell lymphoma using either
IMRT or 3DCRT. Tomita et al. [16] found that IMRT
achieved significantly better dose coverage in terms of
V90% and V95% compared to 3DCRT. Consistent with
these findings, the current study observed improved
V95% dose coverage with IMRT in NK/T-cell lymphoma
(85.40±27.04% for 3DCRT vs. 96.17±13.36% for IMRT,
P=0.02). However, the clinical results from this long-LCP









o or more neighboring anatomic structures(paranasal sinuses, nasopharynx,
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coverage of IMRT failed to provide consequently im-
proved local control and overall survival, as IMRT was
not associated with LCP and OS in both the univariate
and multivariate analysis.
Salivary gland hypofunction and xerostomia have been
shown to be common adverse events related to external
radiotherapy in the head and neck region and can affect
a patient’s oral health-related quality of life [21]. In our
study, the parotid Dmean value was strictly limited within
the constraint of 26 Gy for both IMRT and 3DCRT,
which, in combination with the low total dose of 50 Gy
delivered to cases of NK/T-cell lymphoma, may have
contributed to the lack of parotid sparing associated
with IMRT. We observed superior parotid avoidance in
treatment planning of IMRT group among 18 patients
who underwent cervical region irradiation. This result
might be attributed to the neighboring PTV to parotid
glands in cervical irradiation planning. It implied a
higher parotid Dmean for the both plannings, and IMRT
might take advantage of better OAR protection.
However, it was difficult to analyze differences in the
xerostomia rate between these two groups due to the
small sample size of only 18 patients. Nonetheless, our
results suggest that IMRT may reduce parotid gland
hypofunction when the cervical region is included in the
treatment volume, although this advantage should be
more carefully examined in additional cases of cervical
irradiation.
Although most reports do not clearly delineate the radi-
ation field, a majority of researchers prefer the extended
radiation field [2,4,7,10]. In addition, a total dose equal to
or greater than 45–50 Gy was shown to achieve excellent
local control in previous trials [7,11]. Based on these data,
our institution designed a radiotherapy schedule with a
prescribed dose of 50 Gy and the use of a regional field
that encompassed the anatomic structure(s) involved as
well as adjacent structures. Using this schedule, dramatic
responses to radiotherapy were observed for patients in
both the 3DCRT and IMRT groups. Of the patients who
received combined therapy, the low CR rate after induc-
tion chemotherapy increased following the completion of
definitive radiotherapy. Moreover, adequate local control
and OS were achieved. These results suggested that radio-
therapy performed according to this RT schedule provided
good treatment outcomes for patients with NK/T-cell
lymphoma, regardless of whether IMRT or 3DCRT was
applied. Moreover, OARs were strictly kept within the safe
dose range for both treatment groups, and no severe
toxicity was observed at subsequent follow-up visits.
Therefore, 3DCRT was shown to be as safe as IMRT using
this radiotherapy schedule for NK/T cell lymphoma.
Together, these results suggest that IMRT failed to de-
monstrate any advantages over IMRT for the treatmentof NK/T cell lymphoma. In addition, these techniques
were equivalent in terms of both local control and redu-
cing the rate xerostomia, which is inconsistent with pre-
vious results in patients with head and neck cancer [12].
High sensitivity to radiation and a lower prescribed dose
for lymphoma treatment likely made any advantages of
IMRT difficult to detect. Considering its easier treatment
planning and time-sparing, 3DCRT could be recom-
mended for most cases of NK/T-cell lymphoma. Sa-
tisfying levels of local control were achieved using
definitive radiotherapy in some recent studies, including
ours [4,5]. However, the relatively high distant failure
rate of 24.5% in the current study represents one
remaining obstacle related to this type of treatment and
highlights the need to improve systemic treatment op-
tions. Moreover, chemotherapy regimens that do not
contain anthracycline have demonstrated advantages in
recent studies [22,23]. Although the DICE regimen was
not found to be significant factor associated with im-
proved OS in the current study, this relationship will be
further studied in prospective, randomized clinical trials
at our institution.
Conclusions
This research demonstrated that radiotherapy using a
regional field to a total dose of 50 Gy was effective and
safe, using either 3DCRT or IMRT, for patients with stage
I-II NK/T-cell lymphoma. IMRT demonstrated the advan-
tage of better dose coverage, although this was not asso-
ciated with improvements in LCP or OS. Furthermore,
IMRT may have potential of reducing parotid gland
hypofuction in cases where the cervical region is included
in the treatment volume. In further study, chemotherapy
regimens should be more carefully investigated with the
goal of improving systemic treatment.
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